A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

NCT01279616 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped PI moving to a different institution.

Conditions

Sickle Cell Disease

Interventions

DRUG: Fludarabine monophosphate
DRUG: Rituximab
DRUG: Busulfan
DRUG: ATG
DRUG: Cyclophosphamide
DRUG: Mycophenolate mofetil
DRUG: Tacrolimus

Sponsor

Nationwide Children's Hospital